ALAB Astera Labs, Inc. Insider Trading

Astera Labs President/COO Sanjay Gajendra sells 400,000 shares for $116.1M on scheduled 10b5-1 plan

Sanjay Gajendra executed 5 separate sales totaling 400,000 shares for $116,119,966.50 on 2026-05-21, reducing his holdings by 24.8% from 1,609,668 to 1,209,668 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-02, making it scheduled rather than discretionary. The stock trades at $318.72, up 49.8% over 30 days and 148.7% over 90 days, significantly outpacing the blended sale price of $290.30. His prior 5 trades at ALAB (all on 2026-05-07) showed 30-day and 90-day returns ranging from +19.0% to +26.6%, illustrating a pattern where post-sale price appreciation has exceeded the execution prices on this ticker.

Sanjay Gajendra (President, COO) executes scheduled 10b5-1 sale: 280,000 ALAB shares for $69,774,014.08

Sanjay Gajendra sold 280,000 shares (280.0K shares) across 6 separate transactions on 2026-05-19 for $69,774,014.08, reducing his holdings from 895,000 shares to 615,000 shares (-31.3%). This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-02, meaning the transactions were scheduled rather than discretionary. The stock currently trades at $297.84, 3.5% above its 52-week high of $287.70, and has gained 55.2% over 30 days and 129.7% over 90 days. At ALAB specifically, Gajendra's prior five sales on 2026-05-07 all showed positive subsequent returns (ranging from 19.0% to 26.6% over 30–90 days), though the current volatility context and scheduled nature of this transaction limit forward-looking inferences.

CEO Mohan Jitendra sells 95,444 shares at blended avg $225.02 for $21,476,948.62

Mohan Jitendra, Chief Executive Officer, executed 17 separate sales on 2026-05-18 totaling 95,444 shares for $21,476,948.62, reducing his ALAB holdings by 6.6% to 1,357,295 shares post-transaction. The current stock price is $287.48, trading +9.4% above the 52-week high of $262.90, and has rallied +63.5% over the past 30 days and +116.8% over the past 90 days. At his prior 5 trades in ALAB, post-sale returns in the 90-day window were +21.8%, +22.5%, +20.1%, +19.3%, and +21.3%, with a timing pattern of 0 of 5 well-timed at the 90-day mark. The multi-transaction structure and volume, executed during a period of exceptional momentum, warrants attention to whether these sales reflect portfolio-level flows or discretionary positioning.

General Counsel at Astera Labs sold 14,076 shares ($3.3M) across 18 transactions on 2026-05-18 at blended avg $231.78 vs current $287.48

Philip Mazzara, General Counsel and Secretary of Astera Labs, executed 18 separate sales totaling 14,076 shares for $3,262,539.72 on a single date (2026-05-18), reducing his holdings by 11.9% from 118,215 to 104,139 shares at an average price of $231.78. The current stock price of $287.48 is now +9.4% above the 52-week high, and the stock has surged +63.5% in 30 days and +116.8% in 90 days since these sales. His prior 5 trades at ALAB (all sells on 2026-04-01) showed 30-day returns ranging from +83.7% to +90.6% and 90-day returns from +121.4% to +129.7%, with 0 of 5 classified as well-timed at the 90-day mark—a notable pattern of selling into sustained appreciation. The scale of this single-day liquidation (18 tranches, $3.3M, spanning prices from $235.36 down to $221.01) suggests a systematic execution rather than opportunistic trading, and the consistent underperformance of his prior timing at this ticker contrasts sharply with the company's fundamentals: revenue growth of +115.1% year-over-year and net income of $80,310,000.00 on quarterly revenue of $308,361,000.00.

CEO Jitendra sells 139,951 shares for $31.3M across 22 transactions via pre-arranged 10b5-1 plan

Mohan Jitendra, Chief Executive Officer of Astera Labs, executed 22 separate sales totaling 139,951 shares for $31,295,011.82 at a blended average price of $223.61 over two trading days (May 18–19, 2026), reducing holdings from 3,929,183 shares to 3,789,232 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning it was scheduled and not discretionary. His prior sells at Astera Labs show 30-day returns of +21.8%, +22.5%, +20.1%, +19.3%, and +21.3% from those May 7 sales, whereas his cross-ticker track record over 20 prior sells averaged +30.5% 30-day returns and +35.3% 90-day returns. The stock now trades at $287.48, up 9.4% from the 52-week high of $262.90 and up 63.5% over the past 30 days, after rising 115.1% annually in revenue and trading at a P/E of 184.28.

President/COO Gajendra Sanjay sells 95,444 shares (6.2% of holdings) for $21.5M at blended average $225.02 on 2026-05-18

Gajendra Sanjay, President and COO, executed 17 separate sales on 2026-05-18 totaling 95,444 shares for $21,476,948.62 at prices ranging from $216.46 to $235.41, with blended average price $225.02. The current price is $287.48, representing +9.4% above the 52-week high of $262.90, and the stock has advanced 63.5% over 30 days and 116.8% over 90 days. His prior sales at ALAB (5 trades on 2026-05-07) subsequently delivered positive 90-day returns ranging from 19.0% to 26.6%, meaning the stock rose after those sales—a pattern that did not align with downside prediction. Post-transaction holdings remain substantial at 1,435,857 shares (1.44M shares), representing a 6.2% reduction in position size.

ALAB President and COO Gajendra Sanjay sells ~49,400 shares in largest 23-trade disposition, marking 138th open-market sale in 36 months with uniformly poor prior timing.

Gajendra Sanjay, ALAB's President and COO, executed a large portfolio reduction by selling approximately 49,400 shares across 23 transactions on a single date, totaling roughly $9.8M in disposition value. The stock at the time was trading well below its 52-week high and has rebounded significantly over the prior three months, providing a backdrop where his sales occurred at elevated prices relative to recent weakness. However, Sanjay's insider trading record reveals a concerning pattern: every single one of his prior five sales at ALAB resulted in the stock rising afterward, meaning each sale was poorly timed from a hindsight perspective—he repeatedly exited before meaningful gains materialized. This is his 138th open-market sale across all holdings in the 36-month window, indicating a predominantly selling insider with no open-market purchases during this period. Notably, the company remains profitable with strong revenue growth, so the sales do not signal distress; rather, they reflect a consistent pattern of liquidation at a director-level executive who has never reversed course to buy back into this stock despite multiple poor-timing outcomes on prior exits.

Astera Labs President and COO Gajendra Sanjay sells $45.7M in shares, continuing a pattern of quarterly dispositions.

Gajendra Sanjay, President and COO of Astera Labs, executed a substantial sale of roughly 230,000 shares for nearly $46 million on a single trading day, marking his 115th open-market sale transaction over the past 36 months with zero open-market purchases in that window. The sale is noteworthy in scale and represents his continuing pattern of regular equity dispositions across quarterly windows. However, Sanjay's track record on timing has been consistently poor: all five of his prior same-ticker sales saw the stock rise in the following 30 and 90 days, indicating that he has repeatedly exited ahead of subsequent gains rather than ahead of declines. The company itself remains profitable with strong revenue growth, and the stock trades well below its 52-week high, having rallied significantly over the past month despite the pullback from earlier peaks. This sale occurs in a financially healthy company rather than one showing operational distress, which limits the signal that might otherwise come from such a large executive disposition.

CEO Mohan Jitendra executes seven-transaction sell totaling 139,951 shares in profitable, high-growth company trading below 52-week highs.

CEO Mohan Jitendra sold nearly 140,000 shares across seven separate transactions, reducing his holdings by about three percent. This sale is notable because Astera Labs is a profitable company with strong year-over-year revenue growth, yet the stock has declined significantly from its 52-week high despite gaining substantially over the prior month. Jitendra's prior sales at this ticker have consistently been poorly timed—every one of his five prior ALAB exits was followed by stock appreciation rather than decline, suggesting he has not historically sold into strength. This current sale, executed at prices spanning a narrow range, adds to his pattern of open-market dispositions: he has now completed 166 open-market sales across his portfolio in the 36-month window with no offsetting open-market purchases. While the absolute dollar amount ($28 million) is material and triggered the filtering threshold for C-suite activity, the modest percentage reduction of holdings and the company's fundamentals suggest this is more of a routine monetization than a clear warning sign about company trajectory.

Director Stefan Dyckerhoff sells ~12,500 shares for $2.5M across six transactions on same day.

Director Stefan Dyckerhoff liquidated approximately 12,500 shares in six transactions, disposing of roughly $2.5M in holdings. This represents the continuation of a consistent selling pattern—all 52 of his open-market transactions over the past three years have been sales, with no purchases. Notably, his prior five sales at this ticker were all poorly timed in hindsight: the stock rose significantly in the weeks and months following each prior exit, suggesting he consistently sold before rallies rather than ahead of declines. The current sale occurs while the company remains profitable with strong revenue growth, and while the stock trades well below its 52-week high despite a steep recent rally. However, the uniformly poor timing on his prior exits at this company raises a question about whether Dyckerhoff's pattern—selling into strength rather than weakness—is likely to repeat, or whether this time the stock continues upward again.